Maxim downgraded Coherus Biosciences to Hold from Buy with a $12 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CHRS:
- Coherus Biosciences price target lowered to $12 from $20 at Truist
- Coherus Biosciences price target lowered to $13 from $20 at H.C. Wainwright
- Coherus Biosciences reports Q3 EPS (27c), consensus (31c)
- Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
- CHRS Earnings this Week: How Will it Perform?